Your browser doesn't support javascript.
loading
Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice.
Abe, Masahiro; Nakamura, Shigeki; Kinjo, Yuki; Masuyama, Yuka; Mitsuyama, Junichi; Kaku, Mitsuo; Miyazaki, Yoshitsugu.
Afiliação
  • Abe M; Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
  • Nakamura S; Department of Infection Control and Laboratory Diagnostics, Tohoku University School of Medicine, Miyagi, Japan.
  • Kinjo Y; Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.
  • Masuyama Y; Department of Bacteriology, The Jikei University School of Medicine, Tokyo, Japan.
  • Mitsuyama J; Jikei Center for Biofilm Science and Technology, The Jikei University School of Medicine, Tokyo, Japan.
  • Kaku M; Pharmaceutical & Healthcare Research Laboratories, FUJIFILM Corporation, Kanagawa, Japan.
  • Miyazaki Y; Research Laboratories, Toyama Chemical Co., Ltd, Tokyo, Japan.
J Antimicrob Chemother ; 74(5): 1327-1332, 2019 05 01.
Article em En | MEDLINE | ID: mdl-30753506
OBJECTIVES: T-2307, a novel arylamidine, shows broad-spectrum activity against pathogenic fungi, including Candida albicans. Ocular candidiasis is one of the serious complications associated with Candida bloodstream infection and is known to be refractory to conventional antifungal agents. The aim of the present study was to clarify the effectiveness of T-2307 against ocular candidiasis using a mouse model. METHODS: We evaluated ocular fungal burden in mice infected with C. albicans that received treatment with antifungal agents [T-2307, liposomal amphotericin B (LAMB) or fluconazole] for 3 consecutive days. We also assessed survival rates of mice after C. albicans infection followed by treatment for 7 consecutive days. In addition, ocular T-2307 concentrations and in vitro effectiveness against C. albicans biofilm formation were evaluated. RESULTS: The ocular fungal burdens were significantly reduced after T-2307 treatment compared with the control group (no treatment received) and were comparable with those observed following treatment with LAMB or fluconazole in both early- and late-phase treatment experiments. In addition, all of the mice treated with antifungal agents survived for 3 weeks after infection, whereas mice in the control group died within 3 days. The ocular T-2307 trough concentration was maintained above the MIC in the infected mice. An in vitro biofilm inhibition experiment showed that T-2307 suppressed C. albicans biofilm formation at the sub-MIC level, which was comparable with amphotericin B. CONCLUSIONS: Given these results in experimental disseminated candidiasis, T-2307 may be an effective treatment against the complication of ocular candidiasis.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Métodos Terapêuticos e Terapias MTCI: Plantas_medicinales Assunto principal: Candida albicans / Candidíase / Infecções Oculares / Amidinas / Antifúngicos Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Base de dados: MEDLINE Métodos Terapêuticos e Terapias MTCI: Plantas_medicinales Assunto principal: Candida albicans / Candidíase / Infecções Oculares / Amidinas / Antifúngicos Idioma: En Revista: J Antimicrob Chemother Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão